Global Enzyme Inhibitor Markets, Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F: Focus on PPIs, Protease, Reverse Transcriptase, Aromatase, Kinase, Neuraminidase, & Statins
October 18, 2022 06:33 ET
|
Research and Markets
Dublin, Oct. 18, 2022 (GLOBE NEWSWIRE) -- The "Enzyme Inhibitor Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global enzyme inhibitor market is expected...
Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress
June 12, 2020 08:30 ET
|
Geron Corporation
For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatmentFor...
Geron to Present at Needham Virtual Healthcare Conference
April 08, 2020 16:30 ET
|
Geron Corporation
MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...
Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones
March 12, 2020 16:05 ET
|
Geron Corporation
MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat,...
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
October 10, 2019 17:30 ET
|
Geron Corporation
MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate...
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
September 30, 2019 16:19 ET
|
Geron Corporation
MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation...
Geron to Present at 2019 Cantor Global Healthcare Conference
September 26, 2019 16:18 ET
|
Geron Corporation
MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...
Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
August 08, 2019 08:08 ET
|
Geron Corporation
MENLO PARK, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate...
Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events
August 01, 2019 16:05 ET
|
Geron Corporation
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019, and recent events. The Company...
Geron to Announce Second Quarter Financial Results on August 1, 2019
July 25, 2019 08:00 ET
|
Geron Corporation
MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2019 financial results after the market closes on...